Subject Index

A

ABT-737, 136
 ACC. *See* Acetyl-CoA carboxylase
 Acetyl-CoA carboxylase (ACC)
 fatty acid metabolism regulation, 93, 96–97
 inhibitor development, 98–99
 non-small cell lung cancer, fatty acid synthesis as metabolic liability, 99–100
 therapeutic targeting, 96, 98–100
 Acetyl-CoA synthetase short-chain family member 2 (ACSS2), therapeutic targeting, 94–95
 ACLY. *See* ATP citrate lyase
 ACSS2. *See* Acetyl-CoA synthetase short-chain family member 2
 Acute lymphoblastic leukemia (ALL), BH3 profiling and apoptosis priming, 137
 Acute myeloid leukemia (AML)
 BRD4
 effectors, 63–64
 function and therapeutic targeting, 61–63
 IDH1 mutations, 88
 ADAMTS1, bone metastasis promotion, 153–155
 AKT, 90, 93, 95, 197, 233
 ALL. *See* Acute lymphoblastic leukemia
 AML. *See* Acute myeloid leukemia
 Anergy, therapeutic targeting, 86
 Aneuploidy, therapeutic targeting, 90
 Angiogenesis
 cell growth in vascularly compromised tumors, 69–70
 innate immunity and antiangiogenic therapy, 22–24
 metabolic endothelial cell adaptation, 23, 25
 metabolic tumor cell adaptations to antiangiogenic therapy, 25–27
 overview in cancer, 21–22
 Antioxidants. *See* Reactive oxygen species
 APC, 320
 APOBEC, 338–339
 Apoptosis
 BH3 proteins
 BCL-2 targeting, 135–137
 profiling, 134–135, 137
 promotion, 132–133
 intrinsic pathway, 131–133
 priming, 133–134, 137–138
 ARID1A, 54–57, 242–243
 Atg7, 75–77
 ATM, 88–89
 ATP citrate lyase (ACLY), therapeutic targeting, 93, 95

Autophagy

 basal autophagy in tumors, 73
 cancer metabolism promotion, 76–77, 383
 macromolecule recycling, 75–76
 prospects for study, 77
 survival in starvation, 73–75
 tumor dependence, 75, 360
 tumorigenesis promotion, 75

B

BAF, 53–58
 BCL-2
 anti-apoptotic activity, 132
 BH3 protein targeting, 135–137
 BCR-ABL, 242, 247, 292, 329
 Bergers, G, interview, 299–300
 BH3 proteins. *See* Mimetics
 Bmal1, 79–80, 82
 BMS-777607, 182
 Bone metastasis
 epidemiology, 151
 genes, 152–153
 osteoclast microRNA studies, 157
 progression mechanisms, 151–152
 tumor–stroma interactions
 ADAMTS1 and MMP-1 promotion of metastasis, 153–155
 therapeutic targeting
 Jagged1, 155–157
 transforming growth factor- β , 155–157
 BRAF, 251, 285, 293–294, 360
 BRCA1, oxidative stress in cancer, 89–90
 BRD proteins
 BRD4
 acute myeloid leukemia
 effectors, 63–64
 function and therapeutic targeting, 61–63
 hematopoietic lineage transcription factor cofactor, 63
 therapeutic targeting, 285, 344–346
 breast cancer
 inhibitors in triple-negative breast cancer, 125–126
 proliferation role in estrogen receptor-positive cancers, 124–125
 functional overview, 123–124
 inhibitor resistance mechanisms, 126–128
 Breast cancer. *See also* Mammary tumor organoid
 BRD proteins
 inhibitors in triple-negative breast cancer, 125–126
 proliferation role in estrogen receptor-positive cancers, 124–125

 circulating tumor cell analysis of intratumoral heterogeneity, 271–272
 classification, 227
 epidemiology, 141
 lineage switching and therapy resistance, 287–288
 mouse models
 basal-like cancer
 BRCA mutations, 143
 PARP inhibitor resistance mechanisms, 144–146
 preclinical trials, 143–144
 invasive lobular carcinoma, 142–144
 mammary tumor organoids, 147–148
 nongermine models, 146–147
 prospects, 148
 xenograft collection and heterogeneity analysis, 227–230
 BRG1, 53, 55, 58
 Brugge, J, interview, 301–302

C

Cancer immunogenomics
 neoantigen prediction, 105–107
 vaccine creation case reports, 107–110
 Cancer stem cell (CSC)
 epithelial-to-mesenchymal transition and stemness, 12–13
 glioblastoma multiforme
 in vivo model, 33
 nestin–green fluorescent protein transgene characterization, 34
 overview, 33
 prospects for study, 34
 therapeutic resistance, 34
 leukemia, 1–2, 5–7
 CD47
 innate immune invasion, 6–7
 leukemic stem cell expression, 1–2
 CDH1, 13–14, 16
 CFI400945, 90
 Cichowski, K, interview, 304–305
 Circulating tumor cells (CTCs)
 overview, 311–313
 single-cell analysis
 intratumoral heterogeneity studies
 breast cancer, 271–272
 pancreatic cancer, 271
 prostate cancer, 270–271
 microfluidic isolation, 269–270
 overview, 269
 prospects for study, 273
 tumor evolution monitoring, 272–273
 Clark, S, interview, 306–308
 Clock, 79–80, 82
 Coffin–Siris syndrome (CSS), 56–57

CpG islands, 306–307
 CRISPR–Cas9
 breast cancer mouse models, 146–147
 large-scale cancer dependency
 functional genomics
 screens, 241–242

CRKL, 238
 CSC. *See* Cancer stem cell
 CSS. *See* Coffin–Siris syndrome
 CTCF, 41, 43–44, 49
 CTCs. *See* Circulating tumor cells
 CTLA4, 295
 Cummings Lecture, 291–295
 CYCLOPS, 243, 285–286
 D2HG. *See* 2-Hydroxyglutarate

E

EGFR, lung cancer mutations, 249–251, 253
 EMT. *See* Epithelial-to-mesenchymal transition
 Epithelial-to-mesenchymal transition (EMT)
 classification, 11
 epithelial trait loss during malignancy, 13–15
 genes, 358–359
 mesenchymal trait acquisition, 15
 metastasis studies, 12
 program redefining, 5
 stemness role, 12–13
 therapeutic targeting, 16–17
 tumor progression, 11–12
 ERK, 302–304
 Evan, G, interview, 309–310
 Exosome
 biogenesis, 275
 double-stranded DNA
 functions, 277–278
 identification, 277
 mutation detection, 277
 prospects for study, 278–279
 drug delivery, 318
 overview, 275–277
 Extracellular matrix. *See* Mammary tumor organoid; Tumor microenvironment

F

FAK, 195–196, 198
 FAM83 oncogenes, 211–212
 FAS. *See* Fatty acid synthase
 Fatty acid synthase (FAS)
 elevation in tumors, 95
 fatty acid synthesis overview, 93–95
 metabolic tumor cell adaptations to
 antiangiogenic therapy, 26
 Fibronectin, 195
FRS2, 238
 Functional genomics, cancer
 challenges, 243
 large-scale cancer dependency screens
 cancer dependency types, 242–243
 CRISPR–Cas9, 241–242
 RNA interference, 239–240
 small molecule screens, 242
 overview, 237–238
 screens for alterations in cancer

allele variants, 238–239
 copy number alterations, 238

G

GATA3, 55
 GBM. *See* Glioblastoma multiforme
 Gleevec, 292
 Glioblastoma multiforme (GBM)
 cancer stem cells
 in vivo model, 33
 nestin–green fluorescent protein
 transgene characterization, 34
 overview, 33
 prospects for study, 34
 therapeutic resistance, 34
 cancer vaccines, 107–110
 cell memory, 32
 lineages, 31
 metabolic tumor cell adaptations to
 antiangiogenic therapy, 25
 progenitor cells, 32–33
 types in mouse models, 31–32
 Glutamine, cancer cell uptake, 67–68
 GSK3 β , 6

H

Haber, D, interview, 311–313
 Hematopoietic stem cell (HSC)
 characterization, 2–3
 Hoxb5 expression in long-term stem
 cells, 4–5
 leukemia mutations, 5
 leukemic stem cell comparison,
 5–7
 TLS cells, 2–3
 transplantation, 1
 HER2, 13
 HGF, 159
 HIF. *See* Hypoxia-inducible factor
 Hoxb5, hematopoietic stem cell
 expression, 4–5
 HSC. *See* Hematopoietic stem cell
HUGL2, 13
 2-Hydroxyglutarate (D2HG), oncogenicity,
 89, 314
 Hypoxia-inducible factor (HIF)
 functional overview, 114
 HIF2 in clear cell renal cell carcinoma
 carcinogenesis role, 115–116
 therapeutic targeting, 116–118
 regulation by VHL and oxygen, 115,
 314
 structure, 114

I

IDH. *See* Isocitrate dehydrogenase
 Innate immunity
 antiangiogenic therapy, 22–24
 therapeutic targeting, 86
 Isocitrate dehydrogenase (IDH), mutation
 effects on ATM and NOTCH,
 88–89
 2-hydroxyglutarate oncogenicity, 89
 mouse models, 88
 tumors, 87–88, 321

J

Jagged1, therapeutic targeting in bone
 metastasis, 155–157
 JQ1, 124–128, 344–346

K

Kaelin, W, interview, 314–318
 Kalluri, R, interview, 317–319
 KEAP1, 164
 c-Kit, hematopoietic stem cell
 expression, 3
KRAS
 lung cancer mutations, 249–251, 253
 pancreatic cancer mutations, 232, 247
 survival of tumors, 360–361

L

LAMA3, 213–214
 Leukemia
 hematopoietic stem cell mutations, 5
 leukemic stem cells, 1–2, 5–6
lgl2, 13
 LKB1, 195
 Long-range epigenetic silencing (LRES),
 prostate cancer, 47–49
 Lowe, S, interview, 320–322
 LOXL2, 199
 Lozano, G, interview, 323–325
 LRES. *See* Long-range epigenetic
 silencing
 Lung cancer
 KRAS mutations, 249–251, 263
 lineage switching and therapy resis-
 tance, 287
 non-small cell lung cancer, fatty acid
 synthesis as metabolic
 liability, 99–100
 Lyden, D, interview, 326–327

M

Macropinocytosis, regulation, 70
 MAGE-A1, 105
 Mammary tumor organoid
 human cells
 extracellular matrix–nucleus
 linkage, 213–215
 formation on three-dimensional
 substrata, 208–210
 morphogenesis assay and
 applications, 210–213
 overview, 207
 mouse models, 147–148
 Mardis, E, interview, 328–330
 Matrix metalloproteinases (MMPs)
 MMP-1 and promotion of bone
 metastasis, 153–155
 MMP-9, 210
 MCT cotransporters, 192
Mdm2, 37–38
 MED1, 126
 MET, 170, 182, 327
 Microenvironment. *See* Tumor
 microenvironment

- MicroRNA, osteoclast microRNA in bone metastasis, 157
- Mitochondrial outer membrane permeabilization (MOMP), 131–132, 135
- MMPs. *See* Matrix metalloproteinases
- MOMP. *See* Mitochondrial outer membrane permeabilization
- Morrison, S, interview, 331–333
- MSP, 179–180
- MTAP*, 243
- mTORC1
cell growth effector, 71
lysosomal protein degradation regulation, 70
- MYC, 310
circadian clock perturbation, 79–80
timing of metabolic therapies, 80–82
- N**
- NADPH, regeneration, 168–170
- Navitoclax, 136–137
- ND-646, 99–100
- Neel, B, interview, 334–335
- NHE1, 192
- NOTCH, 88–89
- NRF2, 164–165, 167–168, 232–233, 284
- Nrp1, 22, 47
- Nutrient uptake, cancer cells
glucose, 67–68
glutamine, 67–68
macropinocytosis regulation, 70
nutrient depletion survival, 68–69, 71
signal transduction, 67–68
- O**
- Olaparib, 144–145
- Oncogene mutations
agonistic synthetic lethality, 252
general features, 247–248
genotype complexities, 248
lung cancer mutually exclusive oncogenes, 248–252
patterns and mutual exclusivity, 248
prospects for study, 253–254
- Organoid. *See* Mammary tumor organoid
- OTX-015, 62
- Oxidative stress. *See* Reactive oxygen species
- P**
- p53, 142, 320–321, 323–325, 352
DNA damage response, 38
Mdm2 alleles and physiological outcomes, 37–38
tumor suppressor pathway, 38–39
turnover, 37
- Pancreatic cancer
challenges and opportunities for study, 233–234
circulating tumor cell analysis of intratumoral heterogeneity, 271
KRAS mutations, 232
mouse models, 231–232
- Nrf2 in progression, 232–233
organoid models, 231–232
tumor microenvironment, 233
- Parada, L, interview, 336–337
- PARP inhibitors, 143–144, 301
- PATJ*, 13
- PAX8*, 238
- PBAF, 53–54
- PD-L1, 300
- PDGF, 164, 190, 194
- PDGFR β , 258
- PFKFB3, 23, 25
- PGC-1 α , 170
- PHGDH, 168
- PIK3CA*, 238
- PLXNA2*, 49
- PRMT5*, 243
- Prostate cancer
circulating tumor cell analysis of intratumoral heterogeneity, 270–271
differential chromatin interactions, 44, 46–47
long-range epigenetic silencing, 47–49
topologically associated domain disruptions, 41–45
- PTEN, 90, 164
- PTP1B, 334–335
- R**
- Rac1, 196
- RAD21, 41
- RANKL, 151–152
- Ras, 310
- RCC. *See* Renal cell carcinoma
- Reactive oxygen species (ROS)
antioxidants
clinical trials in cancer prevention, 165–166
treatment, 165, 167
defenses, 164–165
cancer initiation and progression role, 167
handling in cancer cells, 87, 168–170
metastasis role, 167–168
serine limitation effects, 352
sources, 163–164
therapeutic targeting, 89–90
- Receptor d'origine nantais (RON)
cancer activation, 179–180
cell-autonomous versus non-cell-autonomous functions in cancer progression, 181–182
history of study, 177
signaling
downstream pathways in cancer progression, 180–181
ligand-dependent versus ligand-independent, 179
structure, 177–178
therapeutic targeting, 182–183
- Renal cell carcinoma (RCC)
clear cell carcinoma
genetics, 113–114
HIF2
carcinogenesis role, 115–116
therapeutic targeting, 116–118
metabolic tumor cell adaptations to antiangiogenic therapy, 26
- RNA interference
drug target screens
identification of targets, 258–260
therapeutic index establishment
inducible and reversible transgenic mice, 263, 265–266
liver regeneration studies, 262–264
overview, 262
validation
in vitro, 260–261
in vivo, 261–262
large-scale cancer dependency screens, 239–240
- RNF213, 335
- ROCK, 355
- RON. *See* Receptor d'origine nantais
- ROS. *See* Reactive oxygen species
- S**
- Sawyers, C, Dorcas Cummings Lecture, 291–295
- SDF-1, 195
- Single-cell analysis. *See* Circulating tumor cells
- SMAD4, 190
- SMARCB1, 53–55
- SOD. *See* Superoxide dismutase
- SREBPs. *See* Sterol regulatory element-binding proteins
- Sterol regulatory element-binding proteins (SREBPs), 93
- STK11*, 250
- Stratton, M, interview, 338–340
- Superoxide dismutase (SOD), 164
- SWI/SNF
gain-of-function, 56
intellectual disability syndrome point mutations, 56–57
overview of mammalian complexes, 53–54
promoter and enhancer state maintenance, 57–58
prospects for study, 58
sequencing studies in cancer, 54–55
tumor suppression, 55–56
- T**
- TAD. *See* Topologically associated domain
- Taverson, D, interview, 31–343
- T-cell
chimeric receptor T-cell therapy, 286–287
paucity in tumors
CXCR3
impairment in colorectal tumor model, 221–222
chemokine mediation of T-cell accumulation, 220–221
inhibition by *CXCR4*, 222–223
immune escape, 219–220
overview, 219
prospects for study, 223–224
therapeutic targeting, 85–86
- Tenascin C, 190–191
- TET2, leukemia mutations, 5

TGF- β . *See* Transforming growth factor- β
 TME. *See* Tumor microenvironment
 Topologically associated domain (TAD),
 prostate cancer disruptions,
 41–45
 Transforming growth factor- β (TGF- β),
 therapeutic targeting in
 bone metastasis, 155–157
 TRAP, 154
 TRIM33, 127
 Tumor microenvironment (TME)
 bone metastasis
 ADAMTS1 and MMP-1
 promotion, 153–155
 niches beyond osteoclastogenesis,
 157–159
 gradients
 chemokines and growth factors,
 190
 directional migration
 alignotaxis, 196
 chemotaxis, 194–195
 durotaxis, 196
 galvanotaxis, 196–197
 haptotaxis, 195–196
 techniques for study, 193–194
 electrical field alterations, 192–193
 extracellular matrix changes, 190–
 191

hypoxia establishment, 192
 overview, 189–190
 pH gradient inversion, 192, 197
 prospects for study, 199–201
 stiffness gradients, 191–192
 therapeutic targeting for metastasis
 prevention
 disruption of gradient, 198–199
 exploitation of gradient, 199
 prediction of metastasis, 197
 receptor and signaling block-
 ade, 197–198
 lineage switching and therapy resis-
 tance, 288
 pancreatic cancer, 233
 prospects for study, 284–285
 therapeutic targeting, 86
 TWIST, 126

V

Vaccines. *See* Cancer immunogenomics
 Vakoc, C, interview, 344–346
 Varmus, H, interview, 347–350
 Vascular endothelial growth factor
 (VEGF), 21–22, 27, 116,
 159, 190, 288, 299–300,
 314–315

VCAM-1, 159
 VEGF. *See* Vascular endothelial growth
 factor
 Venetoclax, 137
 VHL. *See* von Hippel–Lindau protein
 von Hippel–Lindau protein (VHL),
 314
 clear cell renal cell carcinoma genetics,
 113–114
 hypoxia-inducible factor regulation,
 115
 tumor suppression, 114
 Vousden, K, interview, 351–353

W

Warburg effect, 87
 Weaver, V, interview, 354–356
 Weinberg, R, interview, 357–359
 White, E, interview, 360–361

Y

YAP1, 238

Cold Spring Harbor Symposia on Quantitative Biology

Subject Index

Cold Spring Harb Symp Quant Biol 2016 81: 365-368

Access the most recent version at doi:[10.1101/sqb.2016.81.SI](https://doi.org/10.1101/sqb.2016.81.SI)

License

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to:
<http://symposium.cshlp.org/subscriptions>